Business
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugen
About this update from Genprex, Inc.
[{"type":"text","content":"TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy","length":79,"tagName":"p","attribs":{}},{"type":"text","content":"REQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse Studies","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity ","length":58,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, April 20, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid, also referred to as Quar Oze), for the treatment of lung cancer.","length":644,"tagName":"p"},{"type":"image","alt":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_iifL5YQS5ZkyGbI2UcMmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1Mw--/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The identification of TROP2 and PTEN as potential biomarkers for primary resistance to REQORSA may provide invaluable insights for patient selection, enhancing our precision medicine strategy for our lung cancer cli...